Markus Warmuth

Venture Partner at Versant Venture Management LLC

Markus Warmuth

Markus Warmuth

Venture Partner at Versant Venture Management LLC

Overview
Career Highlights

Monte Rosa Therapeutics, Inc.
H3 Biomedicine, Inc.

RelSci Relationships

1444

Number of Boards

3

Birthday

1971

Age

50

Contact Data
Trying to get in touch with Markus Warmuth? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Markus Warmuth likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Versant Venture Management LLC

Relationship likelihood: Strong

Chief Financial Officer at Monte Rosa Therapeutics, Inc.

Relationship likelihood: Strong

Partner at Versant Venture Management LLC

Relationship likelihood: Strong

Managing Director at Versant Ventures (Switzerland) GmbH

Relationship likelihood: Strong

Chairman, Managing Director at Versant Venture Management LLC

Relationship likelihood: Strong

Venture Partner at Versant Venture Management LLC

Relationship likelihood: Strong

Venture Partner at Versant Venture Management LLC

Relationship likelihood: Strong

Partner at Versant Venture Management LLC

Relationship likelihood: Strong

General Partner at New Enterprise Associates, Inc.

Relationship likelihood: Strong

Former Co-President at Aisling Capital Management LP

Relationship likelihood: Strong

Paths to Markus Warmuth
Potential Connections via
Relationship Science
You
Markus Warmuth
Venture Partner at Versant Venture Management LLC
Career History
Chief Executive Officer, President & Director
2020 - Current

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Venture Partner
2020 - Current

Versant Ventures is an active manager which invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements.

President & Chief Executive Officer
2011 - 2018

Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is an American company located in Cambridge, MA, that engages in discovery and development of genomic drugs. Terushige Iike is currently the CEO of the firm.The company says this about itself: H3 Biomedicine, Inc., the U.S.-based precision oncology research and development subsidiary of Eisai Co., Ltd., is solely focused on advancing drugs from bench to bedside. Uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics, H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment.

Public Holdings
Restricted data only for RelSci Enterprise users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Markus Warmuth. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Markus Warmuth's profile does not indicate a business or promotional relationship of any kind between RelSci and Markus Warmuth.